Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Lung Neoplasms 2Testicular Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Liver Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Paclitaxel 68Carboplatin 64pembrolizumab 32Cyclophosphamide 32Bevacizumab 27liposomal doxorubicin 24Cisplatin 24Topotecan 21Gemcitabine 21olaparib 18fludarabine 17Taxes 16Docetaxel 15Nivolumab 14Doxorubicin 14niraparib 13veliparib 12Albumin-Bound Paclitaxel 11aldesleukin 9Filgrastim 9fludarabine phosphate 8durvalumab 8Oxaliplatin 8Fluorouracil 8Drug Therapy 8sargramostim 7Peripheral Blood Stem Cell Transplantation 7Magnetic Resonance Spectroscopy 7Leucovorin 7talazoparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Ovarian Neoplasms × Mesothelin × Clear all
NCT05410717 2024-06-25

CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors

Second Affiliated Hospital of Guangzhou Medical University

Phase 1 Recruiting
200 enrolled
GenitourinaryGynecologic

Ovarian Neoplasms, Testicular Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡